🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

GAUDIUM IVF N WOMEN H L GAUDIUMIVF NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.gaudiumivfcentre.com
Company Profile ↓
₹131.00
+63.22% 1Y
Mkt Cap₹953.51 Cr
P/E33.42
P/B5.47
52W High₹158.16
52W Low₹70.67
Book Value₹24.42
EPS (TTM)₹3.92

Company Overview

Gaudium IVF and Women Health Limited provides in vitro fertilization (IVF) treatment in India. The company offers fertility and reproductive health services, including intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction; polycystic ovarian syndrome (PCOS)/ polycystic ovarian disease (PCOD); endometriosis treatment; ovulation induction; and laser assisted embryo implantation services. It also provides male infertility treatment services; infertility surgeries; egg freezing; surrogacy; and laparoscopic and hysteroscopic surgeries for the diagnosis and treatment of infertility-related conditions, as well as offers genetic testing options, including preimplantation genetic testing (PGT); and IVF consultancy services. In addition, the company operates hospital, in-house pharmacy; and 7 hubs (IVF centers) and 28 spokes. The company was founded in 2009 and is based in headquartered in New Delhi, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 24.7%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 23.1%.

Consistent Profit Growth

Net profit has compounded at 21.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 33.1% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 33.4, below the sector median of 35.9.

Healthy Margins

Maintains a net profit margin of 23.4%.

Recent Developments

  • Mar 2026 Revenue of ₹104.36 Cr (+47.6% YoY); net profit ₹24.49 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +12.7%, earnings +27.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 33.1%, profit CAGR 21.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:33.12%
1 Year:12.70%

Compounded Profit Growth

5 Years:21.88%
1 Year:27.60%

Stock Price Performance

1 Year:+63.22%
6 Months:-
3 Months:+9.15%
1 Month:+6.73%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 69% of range
₹70.67 ₹158.16
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)46.89 · Neutral
Price Performance
1M+6.73%
3M+9.15%
1Y+63.22%
Valuation vs Sector

P/E of 33.42 is below the sector median of 35.94 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 24.7%.
  • Healthy ROCE of 23.1%.
  • Excellent profit margin of 23.4%.
  • Compounding revenue at 33.1% over 5 years.
  • Profit CAGR of 21.9% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
33.42
Industry PE
35.94
Forward P/E est.
26.19
PEG Ratio
-
Book Value
₹24.42
Price to Book
5.47
P/S
9.32
EV/EBITDA
22.52
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
33.12%
Profit 5Y
21.88%
Revenue (YoY)
12.70%
Earnings (YoY)
27.60%

Profitability & Returns

ROCE
23.09%
ROE
24.66%
ROA
15.60%
Profit Margin
23.44%
Op Margin
38.01%
Gross Margin
52.05%
EPS (Latest Qtr)
₹1.34
EPS (TTM)
₹3.92

Balance Sheet & Liquidity

Debt/Equity
0.16
Quick Ratio
1.61
Current Ratio
1.90
Debt
₹24.57 Cr
Total Assets
₹193.10 Cr
Current Assets
₹73.30 Cr
Working Capital
₹34.77 Cr

Ownership

Promoter Holding
91.86%
Chg in Prom Hold
-
FII / Inst Holding
1.74%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹953.51 Cr
Total Revenue (TTM)
₹104.36 Cr
EBITDA
₹37.70 Cr
Free Cash Flow
₹-7.69 Cr
Operating Cash Flow
₹7.25 Cr
Shares Outstanding
₹7.28 Cr
Gross Margin
52.05%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GAUDIUMIVF GAUDIUM IVF N WOMEN H L NSEPHARMA 131.00 33.42 ₹953.51 Cr 0.00% 23.09% 24.66% 33.12% 21.88%
2 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,974.50 66.71 ₹1.29 L Cr 0.22% 19.79% 21.50% 15.33% 33.34%
3 ALKEM Alkem Laboratories Limited NIFTY_MIDNSEPHARMA 5,597.50 29.07 ₹66,926.51 Cr 0.35% 18.56% 17.56% 8.30% 32.74%
4 ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA 27,855.00 38.12 ₹59,189.93 Cr 1.89% 41.87% 34.46% 9.01% 17.80%
5 ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA 825.65 81.26 ₹46,377.90 Cr 0.24% 26.77% 19.45% 26.20% 15.39%
6 AJANTPHARM Ajanta Pharma Limited NIFTY_MIDNSEPHARMA 3,470.40 38.28 ₹43,357.66 Cr 1.86% 29.41% 23.33% 13.40% 21.55%
7 AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA 532.30 127.96 ₹16,875.30 Cr 0.00% 9.74% 6.58% 26.96% 12.28%
8 APLLTD Alembic Pharmaceuticals Limited NSEPHARMA 834.45 23.67 ₹16,402.21 Cr 1.49% 12.77% 12.36% 9.46% 25.42%
9 ALIVUS Alivus Life Sciences Limited NSEPHARMA 1,325.20 27.06 ₹16,265.43 Cr 0.38% 21.78% 16.94% 7.61% 6.53%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Dec 2025Mar 2026
Revenue 14.42 Cr26.92 Cr24.51 Cr30.35 Cr
Cost of Revenue 5.00 Cr14.19 Cr15.11 Cr12.55 Cr
Gross Profit 9.42 Cr12.74 Cr9.39 Cr17.80 Cr
Operating Expenses 4.34 Cr4.38 Cr3.34 Cr6.26 Cr
Operating Income 5.08 Cr8.36 Cr6.06 Cr11.54 Cr
EBITDA 5.66 Cr8.96 Cr6.65 Cr12.35 Cr
Interest Expense 38.99 L43.44 L1.20 Cr1.29 Cr
Pretax Income 4.69 Cr8.16 Cr4.96 Cr10.42 Cr
Tax Provision 1.30 Cr1.70 Cr1.33 Cr2.06 Cr
Net Income 3.40 Cr6.46 Cr3.63 Cr8.36 Cr
Diluted EPS 0.430.810.501.34

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -44.24 Cr47.89 Cr70.72 Cr104.36 Cr
Cost of Revenue -14.12 Cr15.89 Cr27.79 Cr50.04 Cr
Gross Profit -30.12 Cr32.00 Cr42.93 Cr54.32 Cr
Operating Expenses -11.34 Cr14.41 Cr16.35 Cr19.16 Cr
Operating Income -18.78 Cr17.59 Cr26.58 Cr35.16 Cr
EBITDA -20.09 Cr19.54 Cr28.87 Cr38.24 Cr
Interest Expense -34.24 L74.75 L1.39 Cr3.49 Cr
Pretax Income -18.31 Cr16.63 Cr25.43 Cr32.20 Cr
Tax Provision -4.79 Cr6.31 Cr6.25 Cr7.71 Cr
Net Income -13.53 Cr10.32 Cr19.18 Cr24.49 Cr
Diluted EPS 1.111.861.422.40-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -36.63 Cr51.01 Cr88.51 Cr193.10 Cr
Current Assets -18.39 Cr29.52 Cr53.81 Cr73.30 Cr
Cash & Equivalents -15.06 Cr11.86 Cr7.21 Cr8.79 Cr
Inventory -1.50 Cr2.10 Cr7.23 Cr3.54 Cr
Receivables -90.84 L13.59 Cr32.87 Cr53.38 Cr
Total Liabilities -13.90 Cr24.02 Cr42.22 Cr40.80 Cr
Current Liabilities -9.60 Cr19.69 Cr38.01 Cr38.53 Cr
Long Term Debt -2.11 Cr1.93 Cr1.73 Cr0
Total Debt -11.55 Cr17.40 Cr20.61 Cr24.57 Cr
Total Equity -22.73 Cr26.99 Cr46.30 Cr152.30 Cr
Shares Outstanding -7.28 Cr7.28 Cr7.28 Cr7.28 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -23.85 Cr3.44 Cr8.72 Cr7.25 Cr
Investing Cash Flow --15.63 Cr-5.40 Cr-15.17 Cr-87.65 Cr
Financing Cash Flow -5.25 Cr-1.24 Cr1.82 Cr81.98 Cr
Capital Expenditure --15.26 Cr-2.79 Cr-8.88 Cr-6.72 Cr
Free Cash Flow -8.60 Cr65.40 L-16.08 L52.81 L
Net Change in Cash -13.48 Cr-3.20 Cr-4.64 Cr1.57 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -68.1%66.8%60.7%52.1%
Operating Margin % -42.4%36.7%37.6%33.7%
Net Margin % -30.6%21.5%27.1%23.5%
ROE % -59.5%38.2%41.4%16.1%
ROCE % -69.5%56.2%52.6%22.7%

Shareholding Pattern

Insiders
91.86%
Institutions
1.74%
Public Float
21.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GAUDIUMIVF

Google News Mon, 20 Jul 2026

GAUDIUMIVF Stock Price and Chart — NSE:GAUDIUMIVF - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9ETVVWU0ZvVUxjRnB2TEFYdHFSclJ0ckJwTHRxVlZQWUx2WjhsWnNYU2ZmbXl4VGlCU2txajRxNFBycHhVdE5rMW5hWVNKd0NiNW1MWHFDYkhvSW0wVUdmTQ?oc=5" target="_blank">GAUDIUMIVF Stock Price and Chart — NS…

Google News Fri, 05 Jun 2026

Gaudium IVF and Women Health's (NSE:GAUDIUMIVF) Profits May Not Reveal Underlying Issues - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPcWhGTVpKZ3Z3aEdGV1N0SmxtcFM0Z3p4VWNMZmRXdUFZYmNXdDJoR0F3NXZKTjNLZFc0QkhiM2ZEVC1XMVJQT2V6bWxrZnZOUzM0bFhaY3dFODNfd0djV3JNOVNNMEo4azBXa2xoVG92QXdmSDd1VTJmXzJlSXA4RkpsWFF5RjlRS0ZUVW…

Google News ue, 14 Jul 2026

Price Band Hitters, July 14, 2026: Gaudium IVF, Filat Fashions Lead Upper Band Movers - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYnM5OUltVWJfWHFsQ2ZmMUxmN3BNRzJNMUFjTkN1S0R1SjJFR3RQYl9sQ3lkdElmdU9mTjdHNk5wNnRvOURXY1drR2pQTElhVTFVcDlsTHlYdjI4MnpnNVdTV0ItMGZBenQ0WE1oZFR0aFd2TjZBYnkzVThIT01QRlY5bVlVYlRSRVZHOE…

Google News hu, 09 Apr 2026

GDN Ventures buys 1.37% shares in Gaudium IVF and Women Health - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOa1FfWmdTSmpGYzdGZU9xVmZOaDBIQlotV0FxUzNQcWZIRnpGSTNpS0hwWVgtU3Q4ay0xakdtTFVoT2c4NmZmQW9vMldLdzhGZ3RaejdlZHdsdEVEUnE2N01ZdjNJWnplTnN1S0RXOU9hVC1pdm9XbmpJbkRJZWZSandJT1NwSjd6VWszNk…

Google News hu, 16 Apr 2026

Gaudium IVF and Women Health Limited Clarifies Share Price Movement is Market Driven - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZ2hTTHJrb1FGYnI4N013UHdHSzNIRHYzN2xXMXM0Yl9hZUZNVlpzS05yREZQMzVEal90c05nMnlUUjVpY1B6Nk93aVhDd2VyVV8zY2xBb2VRWWRQUmVmT0F2eGVMRkUzck40QnBWRUNtNXl6U3BXTUUtR2dkWUJHMFlmcTU2THBXWUZXek…

Google News ue, 03 Mar 2026

GAUDIUM IVF AND WOMEN HEALTH LTD. Stock/Share price , NSE/BSE Forecast News and Live Quotes - Equitymaster

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQX2VxYWJBZkIzTmZxT2RpYzFyS091eE9BMWRpaUx5LWF2T0lJTk42RVlCdFNZaFVSdU1CUjVXOFBSWVBKZW83YWRNd05TbHFLMmg1algxdHRDRm0wR3VQRXo5dTZpc01zYkprVUlrejVJZl9RbkdheGY4OUd3U1lCZnJJdUUyZ1JNNnBvOW…

GAUDIUMIVF — Frequently Asked Questions

What is the current share price of GAUDIUM IVF N WOMEN H L (GAUDIUMIVF)?

As of 2026-08-07 06:31 IST, GAUDIUM IVF N WOMEN H L (GAUDIUMIVF) trades at ₹131.00 on NSE. Its 52-week range is ₹70.67 to ₹158.16.

What is the market capitalisation of GAUDIUMIVF?

GAUDIUM IVF N WOMEN H L (GAUDIUMIVF) has a market capitalisation of ₹953.51 Cr on NSE.

What is the P/E ratio of GAUDIUMIVF?

GAUDIUMIVF trades at a trailing price-to-earnings (P/E) ratio of 33.42. The industry average P/E is 35.94. Its price-to-book (P/B) ratio is 5.47.

What is the return on equity (ROE) of GAUDIUMIVF?

GAUDIUMIVF has a return on equity (ROE) of 24.66%. Its return on capital employed (ROCE) is 23.09%.

Is GAUDIUMIVF a good stock to buy?

This page provides a data-driven analysis of GAUDIUM IVF N WOMEN H L (GAUDIUMIVF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space